Author

A. Schubert

Institution: Dana-Farber Cancer Institute

Observed institution: Dana-Farber Cancer Institute

OpenAlex ID: A5136659017

Abstract RF5-02: Tbcrc 056: a phase 2 study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: results from the TNBC cohorts

2026 · E. L. Mayer, N. Graham, et al. · Clinical Cancer Research · 4

LBA4 Efficacy and safety of sacituzumab govitecan (SG) plus trastuzumab in patients with HER2+ metastatic breast cancer after prior trastuzumab deruxtecan (T-DXd): Results from the phase II SATEEN trial

2026 · P. Tarantino, L. Yu, et al. · ESMO Open · 2

Works count: 2

Citation count: 6

H-index: 2

I10-index: